All In Biotech

Drug Trial Radar · NCT00663130

Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)

A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction

Last checked: Nov 19, 2026Latest source record: Oct 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 759 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

759

Actual

Start

Apr 2004

Primary completion

Jul 2004

Study completion Jul 2004

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Apr 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluating the efficacy of 10mg vardenafil versus 10mg tadalafil in the first 45 minutes post-dosing, in an as-required regimen for 4 weeks in subjects with mild/moderate to severe ED

Conditions

  • Erectile Dysfunction

Interventions

  • Levitra (Vardenafil, BAY38-9456)Drug

    Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse

  • TadalafilDrug

    Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sexual Encounter Profile Question 3 (SEP-3)Time frame: 4 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.